Optegra
08 December 2022
Optegra has welcomed a new stakeholder following a definitive agreement by the private equity firm, MidEuropa, to acquire a majority stake in the ophthalmology provider.
H2 acquired a majority stake in Optegra in 2021. Alongside the management team, H2 supported the opening of four UK hospitals, two ‘bolt-on’ acquisitions and a further acquisition in Slovakia, which was a new territory for the ophthalmology group.
As part of the transaction, H2 will become a minority investor alongside management of the company, who will continue to lead Optegra.
The transaction is subject to customary competition and regulatory approvals, and is expected to complete in the first half of 2023.
CEO of Optegra, Dr Peter Byloos, commented: “We have built a strong foundation with H2 Equity Partners and we look forward to welcoming MidEuropa to accelerate our expansion and continue our strong engagement with our doctors, clinical teams and staff.”
Optegra operates in the UK, Poland, Czech Republic, and Slovakia, with 29 facilities performing more than 100,000 surgical procedures per year.
Eye care procedures range from cataract to age-related macular degeneration, and vision correction, for public and private patients.
The company plans to grow into new geographies and build on its presence in existing markets.
Pawel Malicki, principal at MidEuropa, said: “Optegra is a fast-growing European healthcare player ideally positioned to deliver organic growth within its current footprint and expand into new geographies.”
“We have closely followed Optegra’s development over the past few years and are impressed with its progress and excited to work with the management and H2 Equity Partners in building a pan-European ophthalmology champion,” Malicki added.
This autumn, Lexum, part of the Optegra group, entered the Slovak market with the acquisition of the Sokolík Eye Clinic.
H2 acquired a majority stake in Optegra in 2021. Alongside the management team, H2 supported the opening of four UK hospitals, two ‘bolt-on’ acquisitions and a further acquisition in Slovakia, which was a new territory for the ophthalmology group.
As part of the transaction, H2 will become a minority investor alongside management of the company, who will continue to lead Optegra.
The transaction is subject to customary competition and regulatory approvals, and is expected to complete in the first half of 2023.
CEO of Optegra, Dr Peter Byloos, commented: “We have built a strong foundation with H2 Equity Partners and we look forward to welcoming MidEuropa to accelerate our expansion and continue our strong engagement with our doctors, clinical teams and staff.”
Optegra operates in the UK, Poland, Czech Republic, and Slovakia, with 29 facilities performing more than 100,000 surgical procedures per year.
Eye care procedures range from cataract to age-related macular degeneration, and vision correction, for public and private patients.
The company plans to grow into new geographies and build on its presence in existing markets.
Pawel Malicki, principal at MidEuropa, said: “Optegra is a fast-growing European healthcare player ideally positioned to deliver organic growth within its current footprint and expand into new geographies.”
“We have closely followed Optegra’s development over the past few years and are impressed with its progress and excited to work with the management and H2 Equity Partners in building a pan-European ophthalmology champion,” Malicki added.
This autumn, Lexum, part of the Optegra group, entered the Slovak market with the acquisition of the Sokolík Eye Clinic.
Comments (0)
You must be logged in to join the discussion. Log in